|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang H, Shah S and Hilt DC: Organization,
sequence, and expression of the murine S100 beta gene.
Transcriptional regulation by cell type-specific cis-acting
regulatory elements. J Biol Chem. 268:20502–20511. 1993.PubMed/NCBI
|
|
3
|
Boucherat O, Montaron S, Bérubé-Simard FA,
Aubin J, Philippidou P, Wellik DM, Dasen JS and Jeannotte L:
Partial functional redundancy between Hoxa5 and Hoxb5 paralog genes
during lung morphogenesis. Am J Physiol Lung Cell Mol Physiol.
304:L817–L830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ordóñez-Morán P, Dafflon C, Imajo M,
Nishida E and Huelsken J: HOXA5 counteracts stem cell traits by
inhibiting wnt signaling in colorectal cancer. Cancer Cell.
28:815–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen H, Zhang H, Lee J, Liang X, Wu X, Zhu
T, Lo PK, Zhang X and Sukumar S: HOXA5 acts directly downstream of
retinoic acid receptor beta and contributes to retinoic
acid-induced apoptosis and growth inhibition. Cancer Res.
67:8007–8013. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang CC, Su KY, Chen HY, Chang SY, Shen
CF, Hsieh CH, Hong QS, Chiang CC, Chang GC, Yu SL and Chen JJ:
HOXA5 inhibits metastasis via regulating cytoskeletal remodelling
and associates with prolonged survival in non-small-cell lung
carcinoma. PLoS One. 10:e1241912015.
|
|
7
|
Loh M, Liem N, Vaithilingam A, Lim PL,
Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, et al: DNA
methylation subgroups and the CpG island methylator phenotype in
gastric cancer: A comprehensive profiling approach. BMC
Gastroenterol. 14:552014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng QY, Hu ZX, Song XL and Pan HW:
Aberrant expression of genes and proteins in pterygium and their
implications in the pathogenesis. Int J Ophthalmol. 10:973–981.
2017.PubMed/NCBI
|
|
11
|
Marhaba R, Klingbeil P, Nuebel T,
Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM:
Cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simon T, Gagliano T and Giamas G: Direct
effects of anti-angiogenic therapies on tumor cells: VEGF
signaling. Trends Mol Med. 23:282–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Pan K, Wang P, Cao Z, Wang W, Wang
S, Hu N, Xue J, Li H, Jiang W, et al: HBP1-mediated regulation of
p21 protein through the Mdm2/p53 and TCF4/EZH2 pathways and its
impact on cell senescence and tumorigenesis. J Biol Chem.
291:12688–12705. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta A, Kaur CD, Jangdey M and Saraf S:
Matrix metalloproteinase enzymes and their naturally derived
inhibitors: Novel targets in photocarcinoma therapy. Ageing Res
Rev. 13:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spitzwieser M, Pirker C, Koblmüller B,
Pfeiler G, Hacker S, Berger W, Heffeter P and Cichna-Markl M:
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human
cancer cell lines, multidrug-resistant cell models and tumor,
tumor-adjacent and tumor-distant tissues from breast cancer
patients. Oncotarget. 7:73347–73369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang ML, Nie FQ, Sun M, Xia R, Xie M, Lu
KH and Li W: HOXA5 indicates poor prognosis and suppresses cell
proliferation by regulating p21 expression in non small cell lung
cancer. Tumour Biol. 36:3521–3531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ilson DH: Angiogenesis in gastric cancer:
Hitting the target? Lancet. 383:4–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mikhail S, Albanese C and Pishvaian MJ:
Cyclin-dependent kinase inhibitors and the treatment of
gastrointestinal cancers. Am J Pathol. 185:1185–1197. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okimoto RA, Breitenbuecher F, Olivas VR,
Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J,
Tulpule A, et al: Inactivation of Capicua drives cancer metastasis.
Nat Genet. 49:87–96. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang B, Chen Q, Cao Y, Ma X, Yin C, Jia Y,
Zang A and Fan W: LGR5 is a gastric cancer stem cell marker
associated with stemness and the EMT signature genes NANOG,
NANOGP8, PRRX1, TWIST1, and BMI1. PLoS One. 11:e1689042016.
View Article : Google Scholar
|
|
21
|
Raman V, Martensen SA, Reisman D, Evron E,
Odenwald WF, Jaffee E, Marks J and Sukumar S: Compromised HOXA5
function can limit p53 expression in human breast tumours. Nature.
405:974–978. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nieto MA: Context-specific roles of EMT
programmes in cancer cell dissemination. Nat Cell Biol. 19:416–418.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aubin J, Déry U, Lemieux M, Chailler P and
Jeannotte L: Stomach regional specification requires Hoxa5-driven
mesenchymal-epithelial signaling. Development. 129:4075–4087.
2002.PubMed/NCBI
|
|
24
|
Teo WW, Merino VF, Cho S, Korangath P,
Liang X, Wu RC, Neumann NM, Ewald AJ and Sukumar S: HOXA5
determines cell fate transition and impedes tumor initiation and
progression in breast cancer through regulation of E-cadherin and
CD24. Oncogene. 35:5539–5551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Xu L and Jiang L: MiR-1271
promotes non-small-cell lung cancer cell proliferation and invasion
via targeting HOXA5. Biochem Biophys Res Commun. 458:714–719. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang HW, Chung M, Kudo T and Meyer T:
Competing memories of mitogen and p53 signalling control cell-cycle
entry. Nature. 549:404–408. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ratti S, Ramazzotti G, Faenza I, Fiume R,
Mongiorgi S, Billi AM, McCubrey JA, Suh PG, Manzoli L, Cocco L and
Follo MY: Nuclear inositide signaling and cell cycle. Adv Biol
Regul. 67:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Waldman T: The inaugural use of gene
editing for the study of tumor suppressor pathways in human
cells-p21WAF1/CIP1. Cancer Res. 76:4598–4601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
LaBaer J, Garrett MD, Stevenson LF,
Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E: New
functional activities for the p21 family of CDK inhibitors. Genes
Dev. 11:847–862. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng F, Ren Q, Wu S, Saeed M and Sun C:
Hoxa5 increases mitochondrial apoptosis by inhibiting
Akt/mTORC1/S6K1 pathway in mice white adipocytes. Oncotarget.
8:95332–95345. 2017. View Article : Google Scholar : PubMed/NCBI
|
